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1. Introduction
This review describes theories of human atherogenesis and experimental results evaluating
gene or protein expression in the pigeon model for spontaneous atherosclerosis. The spontane‐
ous disease in the pigeon differentiates from other animal models that require manipulation
(genetic, nutritional, environmental) to induce the disease state. Both susceptible and resistant
pigeons have been studied with susceptibility being inherited as an autosomal recessive trait.
The aims are to present the pigeon data in comparison to current theories of the human disease.
Atherosclerotic cardiovascular disease is the leading cause of death in economically devel‐
oped countries. The underlying cause(s) remains unclear despite a variety of hypotheses
that have attempted to explain the initiation of atherosclerotic lesions. Many genetic factors
that contribute to lesion progression and the probability of plaque rupture have been identi‐
fied in the general population. All forms of heart disease have a strong familial component.
However, little is known about the specific genes that determine disease predisposition or
how such genes interact with each other and the environment to initiate foam cell formation
in any one individual. Numerous, complex gene-environment interactions are believed to be
involved in the disease [1] and “although there has been considerable success in identifying
genes for the rare disorders associated with atherosclerosis, the understanding of genes in‐
volved in the more common forms is largely incomplete” [2]. New molecular markers need
to be developed in order to identify susceptible individuals prior to the appearance of clinical
symptoms. Until the heritable component of atherosclerosis susceptibility is understood,
correlation of various risk factors with specific metabolic or pathological features will be dif‐
ficult to assess, and prevention efforts will remain equivocal.
© 2013 Anderson et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Theories of human atherogenesis
Many theories have been proposed to explain atherosclerotic lesion initiation in the aorta al‐
though there are model-specific differences in the order of events. The pathological steps
common to all theories of atherogenesis are:
a. Site specific proliferation of intimal smooth muscle cells
b. Elaboration of excessive and/or abnormal extracellular components
c. Accumulation of lipids within and around cells
d. Entry of monocytes/macrophages into area of proliferation
The abnormal accumulation of lipid within smooth muscle and macrophage cells could arise
from increased infiltration (influx), increased retention, decreased efflux, and/or increased
lipid biosynthesis by the cells themselves [3-9].
2.1. Lipid infiltration theory
The lipid infiltration theory states that arterial wall cells will accumulate lipid if there is a
high circulating blood lipid concentration, or a consistently elevated low-density lipopro‐
teins (LDL). In the healthy human aorta, circulating LDL particles are incorporated into vas‐
cular smooth muscle cells (VSMC) by receptor-mediated endocytosis. In atherosclerosis, the
rate of LDL influx could overwhelm these receptors, causing the excess lipid to be taken up
by scavenger receptors. Modified lipoproteins such as oxidized [10], acetylated [11], or par‐
ticularly small (<70 nm) [12], LDL are thought to slip through the loose junctions between
endothelial cells and accumulate in the intima intact. In these cases, because of their altered
conformation, it is hypothesized that the modified LDL molecules are readily incorporated
into VSMC by uncharacterized scavenger receptors. As foam cells develop and burst, mac‐
rophage cells are recruited to the region. The precise mechanism of how cholesterol from
circulating LDL enters the intima to be incorporated in the developing foam cell is not clear.
In addition, the lipid infiltration theory does not, on its own, account for the SMC prolifera‐
tion observed prior to lipid accretion.
If  lipid infiltration of  any type is  coupled with decreased HDL levels,  there  will  be  re‐
duced cholesterol clearance (efflux) from the cells, and the sterol will remain trapped. In
addition,  the  innermost  arterial  cells  are  in  a  state  of  chronic  hypoxia  ]13].  If  the  fatty
acids  released  by  neutral  cholesterol  ester  hydrolase  (NCEH)  are  not  completely  oxi‐
dized,  the  metabolites  will  accumulate  at  an  accelerated  rate  [14],  and  can  potentially
serve  as  substrate  for  endogenous  cholesterol  and/or  triacylglycerol  (TAG)  synthesis.
There is compelling evidence indicating that the increase of intracellular cholesterol is at
least  partly the result  of  biosynthesis,  and not circulating lipoprotein [15]  uptake.  How‐
ever,  this  mechanism  is  not  explained  by  any  of  the  current  theories  of  atherogenesis,
which  are  mainly  focused  on  the  infiltration  and  retention  of  plasma  lipids  and  their
subsequent inflammatory effects.
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2.2. Response to retention theory
The response to retention theory [16] is a proposed explanation for increased circulating
blood lipid retention. According to this theory, as proteoglycans (PG), especially versican
[12, 17], accumulate in the extracellular matrix (ECM) of the proliferating smooth muscle
and recruited macrophage cells, they bind to incoming LDL particles. Electrostatic interac‐
tion between the LDL apoB and the sulfated chains on the core PG protein binds the LDL to
the cell surface [18] where its solubility is decreased [19]. PG-bound LDL is also more likely
to become oxidized, and in either case, the trapped lipoprotein is incorporated into the de‐
veloping foam cell. Presumably the lipid enters the individual cells by the action of scaveng‐
er receptors, but the proponents of this theory do not directly address this element. Despite
this omission, the response to retention theory does provide a concrete mechanism for the
adherence of circulating lipoproteins to the arterial intima. Therefore, advocates of this theo‐
ry [16] claim that essentially all later progression can be traced to the initial attraction of cir‐
culating LDL to ECM proteoglycans.
The aforementioned lipid infiltration and retention theories provide mechanistic evidence of
how lipoproteins can accumulate in the arterial intima, but key steps of atherogenesis are
not addressed. Neither theory offers direct evidence for how cholesterol esters form within
early foam cells, nor do they explain the initial VSMC proliferation prior to lipid accumula‐
tion. Neither theory explains the subsequent entry of monocytes and macrophages to the in‐
filtration region, nor do they explain the predictable locations of lesion development along
the arterial tree.
2.3. Response to injury theory
The observation that both smooth muscle and macrophage cell types were actively recruited
to balloon catheterization sites led to the response to injury hypothesis [20]. According to
this theory, the arterial endothelium is compromised by various perturbations such as envi‐
ronmental chemicals, high concentrations of blood lipids, certain types of bacteria and virus‐
es, autoimmunity, and/or hemodynamic stress [21]. In response, the endothelial cells either
slough off or become porous, allowing the subsequent lipoproteins and macrophages influx
into the arterial intima. Once initial damage has occurred, the exposed intimal cells are in‐
creasingly vulnerable to additional hemodynamic and environmental aggravation, thus per‐
petuating the original injury and eliciting an immune response. Although endothelial
denudation or injury is not necessary for foam cell formation, an obvious and observable in‐
flammatory response seems to exacerbate the developing atherosclerotic plaque during the
disease’s progressive stage.
2.4. Inflammation theory
Atherosclerosis is now considered a chronic inflammatory disease [22], largely because signs
of inflammation occur concomitantly with hypercholesterolemia [23-26] in a variety of ani‐
mal models. This inflammation theory proposes that the immune system is activated as a
direct result of lipid infiltration [27, 28] and so readily explains the presence of monocytes
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and macrophages in the fatty streak. These cells express scavenger receptors that not only
ingest lipid, especially oxidized LDL; they actively secrete cytokines and recruit adhesion
molecules to the region. These actions are thought to be directly responsible for the increase
in extracellular components observed during later stages of atherogenesis [29]. Increasing
complexity of the matrix between cells advances opportunities for proteoglycans to bind
and transform lipid molecules, thereby perpetuating the entire macrophage recruitment and
cytokine signaling process.
In addition to macrophages, endothelial cells, VSMC, and platelets in the developing lesion
are all capable of synthesizing and/or releasing chemoattractants and growth factors [9].
These cellular interactions work together to expand the initial fatty streak to a mature, fi‐
brous plaque over time. The inflammatory response is well correlated with plaque stability,
and there are already blood tests available that will assess the risk of thrombosis based on
the levels of inflammatory markers [30]. However, as with other theories of atherogenesis,
the inflammatory response does not account for the initial VSMC proliferation prior to lipid
accumulation and macrophage recruitment. Nor does it explain that, in humans, early foam
cells are primarily myogenic. For these reasons, the inflammatory theory explains the mech‐
anisms of plaque progression and the likelihood of disease endpoint better than it explains
atherogenesis itself.
2.5. Monoclonal origin theory
A fourth theory of atherogenesis, that has not gained wide acceptance, states that the VSMC
that abnormally proliferate and accumulate lipid are transformed and of monoclonal origin
[31, 32]. The VSMC which develop into foam cells are phenotypically different from their
counterparts in the normal media [33, 34] in that they actively secrete ECM components
such as proteoglycans and collagen [35]. Healthy, fully differentiated VSMC proliferate
slowly and do not synthesize an extensive ECM [36]. Loss of cell cycle control and the ability
to regulate cholesterol metabolism are early hallmarks of cancerous cells, pathological phe‐
notypes that are seen in atherogenesis. However, technological advances in DNA sequence
analyses have confirmed that although VSMC in general are largely heterogenic, subsets of
cells involved in atherogenic events are derived from specific clones [37, 38] that seem to
proliferate in patches [39]. A second observation that supports this controversial theory is
existence of hypo-methylated DNA in atherosclerotic lesions [40]. Decreased methylation is
significantly correlated with increases in transcriptional activity. During cancer develop‐
ment, normally silent oncogenes can be expressed because of under methylation [41]. The
precise atherogenic role of hypo-methylated DNA and clonal VSMC cells is not determined.
Although the  monoclonal  origin  theory  explains  the  proliferation  of  an  altered  popula‐
tion of lipid-accumulating, ECM-producing SMC in the arterial intima, no specific trans‐
formation event or set of pathological conditions have been proposed that would account
for the initial change in differentiation state, methylation status, and/or the increased mi‐
totic rate in a specific VSMC subpopulation. In addition, animal and human examples in
which atherosclerotic  lesions appear  to  regress  [42-44],  are  not  readily  explained by the
monoclonal theory.
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2.6. Smooth muscle cell phenotypic reversion theory
Smooth muscle cell differentiation is a complex process that requires multiple transcription
factors to be successful [45]. The developing embryo’s VSMC are in the synthetic state as
they are actively proliferating and synthesizing their contractile elements, myofilaments,
and ECM to form the arterial intima [35, 46]. Once the blood vessels are fully formed, the
VSMC further differentiate to the contractile state where they stop proliferating and func‐
tion to facilitate muscle contraction in response to stimuli. A healthy vessel wall is able to
maintain both contractility and the quiescent state [34, 47].
During atherogenesis, VSMC seem to revert to the synthetic state where they abnormally
produce an extensive ECM [48]. This phenotypic modulation [35] is believed to occur before
the cells begin to replicate and migrate to the arterial intima, but the stimulus for this change
is unknown. An alternative explanation is that in individuals predisposed to atherosclerosis,
the VSMC never fully differentiate. In either case, modified VSMC are characterized by a de‐
crease in the alpha/beta actin isoform ratio [33, 34, 49, 50] and the loss of the intermediate
filament proteins such as vinculin and desmin [34, 49, 50]. Ongoing efforts have focused on
identifying more VSMC phenotypic markers [36, 45, 51] to clearly define the state of differ‐
entiation including elements driving its change [52, 53]. Despite the narrow focus on the
VSMC role that does not address macrophage recruitment, this idea is a valid attempt to de‐
scribe the earliest cellular atherogenic events [54].
2.7. Hemodynamic stress theory
Hemodynamic stress is a pervasive factor in all atherogenesis theories, because lesions typi‐
cally develop at aortic regions of bi-directional flow. However, if it were simply a matter of
arterial architecture, any organism with a branching aorta would spontaneously develop
foam cells and initiate the atherosclerotic pathology. Because this is not the case, there must
be some as yet unidentified factor intrinsic to the resistant individuals’ vessel wall that can
withstand the low shear stress effects while maintaining the cells in a contractile phenotype.
Many theories explain lipid accumulation in the arterial wall, some describe the preferred
site of fatty streak formation and the appearance of macrophage cells, but none completely
describe the entire series of events that occurs in atherogenesis. Genetic factors clearly influ‐
ence cholesterol metabolism [55], replication rates [56], the immune response [26, 57] and
the mitochondrial oxidative capacity for cellular lipids [58, 59], thereby manifesting an un‐
derlying influence on all aspects of atherogenesis that warrants additional investigation.
3. Pigeon model of atherogenesis
The susceptible-resistant pigeon (Columba livia) model has been employed to understand
genetic components of this disease [60]. White Carneau (WC-As) pigeons develop spontane‐
ous atherosclerosis without known risk factors [61, 62]. The pigeon lesions [63, 64], have
greater similarities to human atherosclerosis than any other animal model of heart disease.
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St. Clair [65] has reviewed multiple studies clearly demonstrating that WC-As susceptibility
resides at the level of the arterial wall. The Show Racer (SR-Ar) pigeon is resistant to the de‐
velopment of atherosclerosis under identical diet and housing conditions, and with similar
blood cholesterol levels [61]. Crossbreeding and backcross experiments demonstrated aortic
atherosclerosis susceptibility to be inherited in a pattern consistent with an autosomal reces‐
sive Mendelian trait [66].
3.1. Differential gene expression
Representational Difference Analysis (RDA) was used in reciprocal experiments to identify
genes expressed differentially between WC-As and SR-Ar aortic VSMC. Difference products
were cloned, sequenced and identified by BLAST against the chicken genome. We found 134
genes with differential expression. An abridged list of the seventy-two transcripts upregu‐
lated in WC-As (Table 1) included caveolin (CAV1) and enolase (ENO1). CAV1, reported as
WAG-65N20 Clone, was not yet annotated in the original analysis. Its subsequent identifica‐
tion was crucial data because CAV1 represented the biggest difference between breeds. Lu‐
mican (LUM) and cytochrome b (CYTB) were among the sixty-two genes upregulated in the
SR-Ar. The abridged list is shown in Table 2.
We  originally  placed  each  individual  transcript  in  6  thematic  metabolic  pathways  us‐
ing  the  Kyoto  Encyclopedia  of  Genes  and  Genomes  (KEGG)  [67]  and  Pathway  Studio
[68].  These  included  energy  metabolism,  VSMC  phenotype,  transcriptional  regulation,
translational  regulation,  cell  signaling,  and  an  immune  response.  Energy  metabolism
and contractility  pathways  exhibited  the  most  striking  disparity.  Genes  associated  with
glycolysis  and  a  synthetic  VSMC  phenotype  were  expressed  in  WC-As  cells  whereas
SR-Ar  cells  expressed  genes  indicative  of  oxidative  phosphorylation  and  a  contractile
VSMC  phenotype.  In  WC-As  cells,  the  alternatives  of  insufficient  ATP  production  lim‐
iting  contractile  function  or  the  lack  of  functional  contractile  elements  down-regulating
ATP  synthesis  cannot  be  distinguished  due  to  the  compressed  in-vitro  versus  in-vivo
developmental  time frame.  However,  the genetic  potential  for  effectively coupling ener‐
gy  production  to  muscle  contraction  present  in  the  resistant  SR-Ar  was  lacking  in  the
susceptible  WC-As [69,  70].
For this review, we employed the Metacore database [71] from GeneGo (Carlsbad, CA) to
automatically place genes into networks according to their biological function and known
interactions. Monosaccharide catabolism, translation, and multicellular organism develop‐
ment were the most significant biological processes operating in the WC-As VSMC (Table
3). Monosaccharide catabolism was represented by ENO1, lactate dehydrogenase A
(LDHA), transketolase (TKT1), and glucose-phosphate isomerase (GPI). Fourteen genes in‐
volved in translation were upregulated in our experiment including ribophorin (RPN1), Li‐
gatin (LGTN), and a number of ribosomal proteins. Although many genes participate in
multicellular organism development, 46 were upregulated in the WC-As including cyclin D
(CCND2), annexin (ANXA2), collagen (COL5A2), beta actin (ACTB), vimentin (VIM), trans‐
membrane protein 126a (TMEM126A), subunit 3 of the 26S Proteasome ATPase (PSMC3)
and diacylglycerol O-acetyltransferase (DGAT2).
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Gene Product Gene WC-As copies SR-Ar copies
Caveolin-1 CAV1 39 1
Enolase, alpha ENO1 30 0
Retinol binding protein 7 RBP7 19 2
Cleavage & polyadenylation specific factor 2 CPSF2 18 0
Mitochondrial ribosomal protein L27 MRPL27 18 0
N-acetyltransferase 13 (aka MAK3) NAT13 18 0
Ribophorin I RPN1 16 0
Stromal cell-derived factor 1 (aka SDF-1) CXCL12 16 2
Diacylglycerol O-acetyltransferase 2 DGAT2 14 0
26S Proteasome ATPase Subunit 2 PSMC2 14 0
Ribosomal Protein Large Subunit 32 RPL32 9 0
Actin, beta ACTB 9 1
Dachshund homolog-1c DACH1 9 1
Annexin A2 ANXA2 8 0
Ligatin LGTN 8 0
Sec61 alpha SEC61A 8 2
Transketolase TKT1 6 0
Collagen, alpha-2 type I COL1A2 6 1
Aldehyde dehydrogenase E3 ALDH9A1 5 1
Solute carrier protein 25/A6 (ATP/ADP antiporter) SLC25A6 5 3
Nucleoside diphosphate kinase CNDPK 4 0
TNF-alpha induced protein 8 TNFAIP8 4 0
Lactate dehydrogenase subunit A LDHA 3 0
Macrophage erythroblast attacher MAEA 3 0
26S Proteasome ATPase Subunit 3 PSMC3 3 0
Spondin 1 SPON1 3 0
Transmembrane protein 167 TMEM167 3 0
Decorin (dermatan sulfate PG) DCN 2 0
Table 1. Genes with the highest differential expression in White Carneau (WC-As) vascular smooth muscle cells
(VSMC) in representational difference analysis abridged from [70].
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Gene Product Gene WC-As copies SR-Ar copies
Ribosomal Protein Large Subunit 3 RPL3 6 73
Lumican Precursor (keratan sulafate PG) LUM 2 47
Cytochrome b CYTB 0 41
Fibulin-5 precursor (aka DANCE) FBLN5 0 30
Fbronectin type 1 FN1 0 29
Cytochrome Oxidase Subunit II CO II 11 28
Lactate dehydrogenase subunit B LDHB 21 25
Peroxiredoxin 1 PRDX1 8 20
NADH subunit 4 ND4 4 19
Eukaryotic translation initiation factor 4A2 EIF4A2 8 19
SMC Myosin Heavy Chain 11 MYH11 0 12
Proteosome maturation factor UMP1 POMP 6 10
Tropomyosin, alpha TPM1 0 9
26S Proteasome Regulatory Lid (non ATPase) PSMD1 0 8
Myosin light chain kinase; telokin MYLK 0 7
Actin, alpha-2 ACTA2 0 6
Coactosin-like 1 COTL1 0 5
Cytochrome Oxidase Subunit I CO I 0 5
Mariner 1 transposase gene (similar to) SETMAR 0 3
RAS oncogene family (GTP binding) RAB1A 0 3
Sec61 gamma SEC61G 0 3
Squalene epoxidase SQLE 0 3
Ribosomal Protein Small Subunit 8 RPS8 1 3
F0-ATP synthase subunits 6 & 8 ATP6/8 2 3
Fatty acid binding protein 4 FABP4 2 3
Prohibitin 2 (aka B-cell receptor protein 37) PHB2 2 3
Activin A/TGFB Receptor 1 ACVR1 0 2
Fumarate hydratase/fumarase FH 0 2
26S Proteasome ATPase Subunit 4 PSMC1 0 2
Table 2. Genes with the highest differential expression in Show Racer (SR-Ar) vascular smooth muscle cells (VSMC) in
representational difference analysis abridged from [70].
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Biological Process
Ratio of significant expressed genes
from total number of genes involved in
process P-value
monosaccharide catabolic process 8/91 4.737E-09
Translation 14/452 6.498E-09
multicellular organismal development 46/4895 6.897E-09
glucose catabolic process 7/69 1.657E-08
system development 41/4195 2.773E-08
alcohol catabolic process 8/114 2.834E-08
developmental process 47/5334 3.512E-08
establishment of protein localization in endoplasmic
reticulum 8/119 3.970E-08
protein targeting to ER 8/119 3.970E-08
anatomical structure development 473/4620 4.356E-08
Table 3. Biological processes (GeneGo, Carlsbad, CA) upregulated in White Carneau (WC-As) vascular smooth muscle
cells (VSMC) based on representational difference analysis.
The most relevant network from the dataset connects 8 identified genetic transcripts (Figure
1) including the extracellular signals decorin (DCN), and chemokine ligand 12 (CXCL12),
the cytoskeletal components ezrin (VIL2), ACTB, and PSMC3, as well as the nuclear tran‐
scripts ENO1, CCND2, and daschund homoglog 1c (DACH1). The expression of ENO1, a
glycolytic enzyme and a transcription factor, is promoted by three separate network factors.
First, its expression is influenced by DACH1 directly. Second, ENO1 is activated indirectly
by CXCL12, where it works through c-src (not in dataset) and ACTB. Finally, DCN, by way
of talin (not in dataset) also activates ACTB. Once expressed, ENO1 participates generally in
monosaccharide catabolism and specifically accelerates cell proliferation via CCND2.
Smooth muscle contraction and myofibril assembly were the most significant biological
processes in the SR-Ar VSMC (Table 4). These pathways included alpha actin (ACTA2), my‐
osin heavy chain (MYH11), tropomyosin (TPM1) and the telekin transcript from myosin
light chain kinase (MYLK). There were also major differences in cellular component organi‐
zation between the two breeds, with the SR-Ar expressing not only MYH11, but LUM, fibro‐
nectin (FN1), high mobility group transcription factor (HMG1), and activin 1, a receptor for
transforming growth factor beta (TGF1), among many others.
The Figure 2 network depicts the critical nature of SP1, a transcription factor known to regu‐
late VSMC differentiation by turning on the gene for myosin heavy chain [73]. Although SP1
was not found in our experiment, a required cofactor, CRSP2, was upregulated in the SR-Ar.
SP1 also appears to influence alpha actin (ACTA2) activity. ACTA2, expressed in contractile
VSMC of SR-Ar does not seem to influence transcription as does the beta isoform, which is
associated with the synthetic phenotype found in Wc-As.
Atherosclerosis-Susceptible and Atherosclerosis-Resistant Pigeon Aortic Smooth...
http://dx.doi.org/10.5772/52948
173
Figure 1. Network analysis (GeneGo, Carlsbad, CA) incorporating genes upregulated in White Carneau (WC-As) vascu‐
lar smooth muscle cells (VSMC) based on representational difference analysis. Abbreviations listed in [72].
Biological Process
Ratio of signifcant expressed
genes from total number of
genes involved in process P-value
smooth muscle contraction 12/76 2.981E-17
muscle contraction 14/258 2.311E-13
myofibril assembly 9/64 1.004E-12
muscle system process 14/305 2.247E-12
cellular component organization at cellular level 38/3480 3.841E-12
skeletal myofibril assembly 6/14 4.050E-12
actomyosin structure organization 9/76 5.025E-12
cellular component organization or biogenesis at cellular level 38/3604 1.144E-11
cellular catabolic process 28/1908 1.199E-11
muscle tissue development 14/347 1.270E-11
Table 4. Biological processes (GeneGo, Carlsbad, CA) upregulated in Show Racer (SR-Ar) vascular smooth muscle cells
(VSMC) based on representational difference analysis.
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3.2. Differential protein expression
DNA transcripts of a species do not directly reveal the protein complexity of that organism
[74]. A more complete elucidation of gene expression can be achieved through characteriza‐
tion of the proteins, the biological determinants of phenotype. Towards that goal, soluble
proteins in aortic smooth muscle cells cultured from WC-As and SR-Ar pigeons were ex‐
tracted and separated on two-dimensional electrophoresis gels.
Proteins differentially-expressed were arrayed on a map, plotting molecular weight against
isoelectric point (pI). Eight discrete zones were identified, five which included proteins
unique to susceptible cells and three which included proteins unique to resistant cells. Of
the 88 differentially-expressed proteins from WC-As cells, 41 were located in unique zones
while 29 of 82 differentially-expressed proteins from Sr-Ar cells were in unique zones. Se‐
lected proteins from susceptibility and resistance zones were annotated by peptide mass
fragments, molecular weights, pIs, and correspondence with genes differentially-expressed
between cells from the two breeds. Eight proteins were unique to the WC-As, and eight pro‐
teins were exclusively expressed in the SR-Ar (Table 5). Some of the annotated proteins in‐
cluded smooth muscle myosin phosphatase (MYPT1), myosin heavy chain (MYH11) –and
fatty acid binding protein (FABP) in the SR-Ar. Ribophorin (RPN1), heat shock protein
(HSP70), cyclin (CCND2) and TNFα-inducing factor (TNF) were found in WC-As [75]. Ribo‐
phorin, cyclin, TNFα Induced Protein 8, FABP and MYH11 were also differentially ex‐
pressed in the RDA experiments and are likely important to the atherosclerotic phenotype in
pigeon VSMC.
Figure 2. Network analysis (GeneGo, Carlsbad, CA) incorporating genes upregulated in Show Racer (SR-Ar) vascular
smooth muscle cells (VSMC) based on representational difference analysis. Abbreviations listed in [72].
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Protein Name Breed
Heat shock protein HSP70 WC-As
Tumor necrosis factor alpha inducing factor TNF WC-As
Mannosidase MAN2BA WC-As
Tropomyosin TPM1 WC-As
Cyclin CCND2 WC-As
Lumican LUM WC-As
Ribophorin RPN1 WC-As
Inhibitor of kappa light polypeptide enhancer in B cells IKBKAP WC-As
Serine threonine kinase STK SR-Ar
Smooth muscle myosin phosphatase MYPT1 SR-Ar
Activin binding protein FST SR-Ar
Myosin heavy chain MHY11 SR-Ar
Serine threonine protein kinase STK24 SR-Ar
Phosphoglucomutase PGM SR-Ar
Fatty acid binding protein FABP SR-Ar
Peroxiredoxin PRDX1 SR-Ar
Table 5. Annotated differentially-expressed soluble proteins extracted from vascular smooth muscle cells (VSMC) of
White Carneau (WC-As) and Show Racer (SR-Ar) pigeons abridged from [75].
All 16 annotated proteins were entered into GeneGo (Carlsbad, CA) to elucidate the meta‐
bolic networks operating in each breed. In the WC-As, regulation of molecular function, reg‐
ulation of inclusion body assembly, and response to unfolded protein were the most
significant biological processes (Table 6). Heat shock protein contributed to each of these
processes, and was joined by CCND2, TPM1, TNF, and inhibitor of kappa light polypeptide
enhancer in B cells (IKBKAP) in overall regulation of molecular function. In addition to
those mentioned previously, TPM1 and IKBKAP were also differentially expressed in the
RDA experiments. The major biological processes operating in the SR-Ar were myosin thick
filament assembly and organization (Table 7), represented primarily by the proteins MHY11
and MYPT1. This was similar to the RDA experiment, where smooth muscle contraction and
myofibril assembly were indicated by multiple genetic transcripts.
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Biological Process
Ratio of significant expressed
genes from total number of
genes involved in process P-value
negative regulation of inclusion body assembly 3/5 1.604E-09
regulation of molecular function 11/2707 5.827E-09
regulation of inclusion body assembly 3/8 8.975E-09
response to unfolded protein 5/156 2.053E-08
response to topologically incorrect protein 5/162 2.481E-08
regulation of catalytic activity 10/2242 2.507E-08
regulation of cellular component biogenesis 6/379 3.864E-08
negative regulation of myeloid cell apoptosis 3/13 4.576E-08
negative regulation of vasoconstriction 3/14 5.822E-08
protein refolding 3-16 8.951E-08
Table 6. Biological processes (GeneGo, Carlsbad, CA) upregulated in proteomic analysis of White Carneau (WC-As)
vascular smooth muscle cells (VSMC).
Biological Process
Ratio of significant expressed
genes from total number of
genes involved in process P-value
skeletal muscle myosin thick filament assembly 4/8 3.53E-12
striated muscle myosin thick filament assembly 4/8 3.53E-12
myosin filament assembly 4/11 1.66E-11
cardiac muscle fiber development 4/11 1.66E-11
elastic fiber assembly 4/11 1.66E-11
myosin filament organization 4/11 1.66E-11
skeletal myofibril assembly 4/14 5.04E-11
extracellular matrix assembly 4/14 5.04E-11
myofibril assembly 4/64 3.15E-08
actomyosin structure organization 4/76 6.34E-08
Table 7. Biological processes (GeneGo, Carlsbad, CA) upregulated in proteomic analysis of Show Racer (SR-Ar) vascular
smooth muscle cells (VSMC).
The major network operating in the protein data set is depicted in Figure 3. This network
shows the cellular signaling cascade initiated by the cytokine TNFα. Although TNFα itself
was not found in either experiment, its activity is suggested by the induced factors ex‐
pressed in the WC-As. The transcription factors c-Jun and Ap-1 activate TNFα, which then
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induces JAK1 gene expression via two receptors, TNFR1 and TNFR2. JAK1 turns on STAT1
and this pathway is known to regulate VSMC inflammatory processes [76]. TNFα also exerts
its biological effect on apoptotic peptidase activating factor 1 (Apaf-1), which induces apop‐
tosis via TRADD and the cellular caspases. This would be a simple story of inflammation
and apoptosis, if it wasn’t for the concomitant HSP70 expression in the WC-As. This heat
shock protein also works through JAK1, but has an inhibitory effect on Apaf-1 [77]. There‐
fore, although Apaf-1 expression is stimulated by c-Jun, both via TNFα and cytochrome c,
HSP70 simultaneously blocks Apaf-1, possibly causing problematic cells to resist apoptosis
and continue to proliferate. This pathway is not present in the SR-Ar.
4. Relevance to atherogenic theories
The idea that susceptible and resistant populations exhibit differences in VSMC differentia‐
tion is vigorously supported by our data. Both experiments showed SR-Ar VSMC to be in
the contractile phase, while this was clearly not the case for WC-As. The WC-As did not ex‐
press myosin-related genes or proteins, and the presence of beta actin correlates with a syn‐
thetic phenotype. Contractility was a major difference in our previous gene analysis [70], so
finding related proteins strengthens this pathway’s relevance to the resistant phenotype.
Contraction depends on the ATP produced by oxidative phosphorylation. Although mito‐
chondrial respiration was a significant biological process in this analysis, monosaccharide
catabolism was upregulated in the WC-As.
Glycolytic enzymes ENO1 and lactate dehydrogenase A (LDHA), both found in the WC-As,
contain hypoxia response elements [78]. This may indicate that during oxygen deficit,
VSMC shift their energy production from oxidative phosphorylation, which has an absolute
oxygen requirement, to glycolysis, which is anaerobic. Glycolysis does not produce enough
ATP to support a contractile phenotype, and the upregulation of ENO1 to support glycoly‐
sis would be problematic, given its dual role as a transcription factor (Figure 1). In the ab‐
sence of oxygen, lipids cannot be fully oxidized which could have a two-fold effect. First,
more substrate is available for cholesterol and TAG synthesis, an idea supported by DGAT2
expression in the WC-As. Second, the increased ROS generation from partially-oxidized lip‐
ids could be triggering the observed WC-As inflammatory pathway.
The theory that atherosclerosis is a chronic inflammatory disease is supported by the data
sets, although the chemokines expressed in the WC-As are secondary indicators of inflam‐
mation, and the primary mediator remains unclear. In addition to the TNF alpha pathway
uncovered in the WC-As proteomics experiment (Figure 3), CXCL12 was significantly upre‐
gulated in the RDA experiments. This is relevant to the human disease as it was recently
identified as a CVD- susceptibility locus in a genome wide association study [79, 80]. Al‐
though newly implicated in atherosclerosis, CXCL12 is thought to exacerbate the probability
of plaque rupture during the advanced stages of the disease [81]. The over-expression of
CXCL12 in the earliest stages of atherogenesis is an important observation in the WC-As, es‐
pecially given that it activates c-src (Figure 1). As described earlier in this review, c-src acti‐
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vates beta actin (synthetic phenotype) and enolase (glycolytic enzyme), and, like ENO1,
CXCL12 has a hypoxia response element in its promoter [82]. CXCL12 has been implicated
in the metastasis and angiogenesis of some cancers, and is an “independent predictor” of
ovarian cancer survival rates [83]. In this capacity, it may contribute to the migration and
proliferation of VSMC that occur early in atherogenesis.
Figure 3. Network analysis (GeneGo, Carlsbad, CA) incorporating annotated differentially-expressed soluble proteins
extracted from vascular smooth muscle cells (VSMC) of White Carneau (WC-As) and Show Racer (SR-Ar) pigeons. Ab‐
breviations listed in [72].
The response to retention theory is marginally supported by the data. Ribophorin and man‐
nosidase expression in both experiments suggests increased glycosylation in the WC-As, a
prerequisite of lipid retention. Lipid retention was further suggested by the expression of
CAV1 in the WC-As. This finding is important because APOE knockout mice studies have
shown that the loss of CAV1 is actually protective against atherosclerosis [84]. Therefore, its
differential expression in the pigeon model may play an important role in the susceptible/
resistant phenotypes. Finally, the response to injury, monoclonal nature, and the effect of he‐
modynamic stress were not tested in either experiment, so their contribution to atherosclero‐
sis in the pigeon model could not be determined.
Gene and protein expression in susceptible and resistant pigeon VSMC support current the‐
ories of human atherogenesis. Many genetic factors have been identified that contribute to
plaque progression, but the gene or genes responsible for initiation of the disease remain un‐
clear. The autosomal inheritance of spontaneous atherosclerosis in the White Carneau sug‐
gests that the affected gene is one having broad effects, such as a transcription factor.
Because pigeon VSMC genes and proteins are differentially expressed prior to foam cell for‐
mation, the pigeon is a valuable model for studying the earliest events of atherogenesis.
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